How inherited retinal dystrophy gene therapy is moving beyond RPE65

What inherited retinal dystrophy gene therapy looks like

Inherited retinal dystrophy (IRD) is a heterogeneous group of conditions caused by mutations in genes affecting retinal structure and function. The principal characteristics:

• More than 250 genes are associated with IRD; the genetic heterogeneity is the commercial-and-clinical complexity
• Each gene-defined IRD has its own clinical phenotype, progression rate, and treatment-eligibility window
• Disease-modifying therapy through gene therapy requires both the correct vector-mediated gene delivery and the right intervention timing relative to disease progression

Voretigene neparvovec (subretinal AAV2 delivery of RPE65 cDNA) was the first commercial validation of the approach. The pipeline beyond RPE65:

• USH2A gene therapy: Programs targeting Usher syndrome type 2A, the most common cause of combined deafness and retinitis pigmentosa
• CEP290 antisense oligonucleotide: ASO targeting the splice-site mutation in CEP290-mediated Leber congenital amaurosis
• RPGR gene therapy: Programs targeting X-linked retinitis pigmentosa
• CHM gene therapy: Programs targeting choroideremia
• ABCA4 gene therapy: Programs targeting Stargardt disease (operationally complex due to ABCA4 size)
• Adjacent programs: Multiple other gene-defined IRD targets at various pipeline stages

The infrastructure that gates uptake

Each IRD gene therapy program faces shared infrastructure constraints:

• Genetic testing infrastructure: Patients must be genotyped to confirm eligibility. Genetic testing capacity for IRD has expanded substantially but is uneven globally and is a real access constraint in many markets
• Subretinal delivery: Most IRD gene therapy programs use subretinal injection, which requires specialist surgical capability and procedure-room access. The number of subretinal-injection-capable centres globally is modest
• Patient-finding pathway: IRD patients are diagnosed at varying ages and often manage their condition outside specialist genetic-eye-disease centres. Connecting the diagnosed population to gene therapy referral is operationally challenging
• Treatment-window timing: Most IRD gene therapy programs benefit most when delivered before substantial photoreceptor loss. Late-stage disease has reduced response potential

What this means for commercial planning

For sponsors of IRD gene therapy programs and adjacent ophthalmic gene therapy:

• The patient-finding and diagnosis pathway is part of the commercial responsibility. Genetic-testing infrastructure investment, specialist-network development, and patient-organisation engagement are commercial inputs
• The surgical-delivery infrastructure is a finite operational resource. Programs benefit from coordinating with adjacent IRD programs on shared subretinal-injection capacity
• The pricing model evolution from one-time-payment toward annuity-style or outcomes-based models is more pronounced in IRD because of the small eligible populations and the durability questions

What we are watching

• Late-stage IRD gene therapy pivotal trial readouts across the multiple gene-defined targets
• Genetic testing infrastructure expansion and the rate of patient-finding pathway maturation
• Subretinal-injection capacity expansion and the rate of new-centre development
• Adjacent ophthalmic gene therapy pipeline beyond IRD (wet AMD, dry AMD, glaucoma) and the lessons that transfer